[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"t-cell-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:t-cell-dysfunction":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100568655",false,"NCT06684054","Studying the Senescent T Cell Features and Its Relationship with the Chemotherapy Efficacy in Young TNBC","Study of the Features of Senescent T Lymphocytes Induced by Chemotherapy and Its Relationship with the Efficacy of Neoadjuvant Chemotherapy in Young Triple-negative Breast Cancer Patients, a Single-center, Observational Study.","STFREiYTNBC","Inclusion Criteria:\n\n1. Female, age≤40 years old,\n2. Invasive breast cancer confirmed by pathology, immunohistochemistry showed TNBC (ER-, PR-, HER2-),\n3. Indications for neoadjuvant chemotherapy according to guidelines: tumor diameter \\> 2cm or with axillary lymph node metastasis or desiring breast-conserving surgery but should obtain negative surgical margins through neoadjuvant chemotherapy.\n\nExclusion Criteria:\n\n1. Stage IV patients or a history of other malignancies,\n2. Having microbial infection or autoimmune disease have not been cured or having HBV, HIV infection,\n3. Having surgery 3 months before enrollment,\n4. Patients with insufficient clinicopathological data,\n5. Does not meet the indications for neoadjuvant chemotherapy or is unwilling to cooperate.",true,"FEMALE","18 Years","40 Years",{"count":21,"type":22},30,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the features of senescent T lymphocytes induced by chemotherapy and its relationship with the efficacy of neoadjuvant chemotherapy in young triple-negative breast cancer (TNBC) patients.\n\nThe main questions it aims to answer are:\n\n* What are the senescent features of peripheral T lymphocytes in young TNBC patients receiving neoadjuvant chemotherapy and the relationship with the efficacy of neoadjuvant chemotherapy?\n* What is the relationship between senescent T cells and adverse events, DFS and tumor infiltrating lymphocytes?\n\n  1. Participants will receive 6 cycles of docetaxel + adriamycin\u002Fepirubicin + cyclophosphamide (TEC\u002FTAC) neoadjuvant chemotherapy, and radical mastectomy after chemotherapy.\n\n2.5ml peripheral venous blood will be collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery.\n\n3.Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study.",[26,27,28],"T-Cell Dysfunction","Chemotherapy Effect","Adverse Events",[30,31,32],"breast cancer","senescence","chemotherapy","NOT_YET_RECRUITING","2024-11-10",{"date":36,"type":37},"2024-11-12","ACTUAL",{"date":39,"type":22},"2025-01-01",{"date":41,"type":22},"2027-12-31",{"name":43,"class":44},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",""]